Viewing nowCombinationTrantaduo Tablet 2.5/500 mg
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Unimed Pharmaceutical Co., Ltd.

MFDS item code 202400702 · Approved 2024.03.29 · Insurance code 649508470
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to help control blood sugar in patients with type 2 diabetes taking both linagliptin and metformin. It supports effective blood sugar management when combined with dietary and exercise therapy. Therefore, this medication is suitable for patients with type 2 diabetes who require blood sugar control.
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, the initial dose of this medicine is 2.5/500 mg twice daily, 1 tablet per dose; the dose may be increased to 2.5/1000 mg twice daily, 1 tablet per dose. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s existing metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 3. Precautions for administration to the following patients in Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Do not administer to the following patients in Precautions for Use).
This medication is primarily used to control blood sugar, as it contains two active ingredients that work together to lower blood sugar levels. This medication can cause a rare but serious side effect called lactic acidosis, so it should not be administered to patients with impaired kidney function or liver dysfunction. Moreover, patients with certain types of diabetes, severe heart disease, acute infections, dehydration, or acute myocardial infarction may be at risk if using this medication. It is not recommended for use in pregnant or breastfeeding women, and consultation with a physician is essential before administration. This medication can cause hypoglycemia, so careful monitoring of blood sugar changes is necessary, especially when used with other hypoglycemic agents or insulin. Elderly patients with impaired kidney function or those taking medications that may affect kidney function should undergo regular kidney function tests. During the course of taking this medication, rare side effects such as acute pancreatitis or blistering dermatitis may occur, so if persistent abdominal pain or skin abnormalities are observed, the physician should be informed immediately. Additionally, this medication may lead to vitamin B12 deficiency, so if used long-term, blood tests to check vitamin B12 levels are necessary. This medication can interact with other drugs, so it is crucial to inform the doctor or pharmacist of any current medications. Patients should avoid excessive alcohol consumption while taking this medication and may need to stop taking it for a certain period prior to surgeries or radiological examinations. Safety in children and adolescents has not been established, so it is not recommended for children under 10 years old. This medication should be stored in a tightly closed container, away from moisture and out of reach of children, and transferring the medication to other containers should be avoided. In case of an overdose, immediate medical attention should be sought, especially if symptoms of lactic acidosis occur.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air and moisture. The storage temperature should be maintained between 1°C and 30°C. This helps maintain the effectiveness and safety of the medication over time.
Light yellow, convex, oval-shaped film-coated tablets
30 tablets/box [(6 tablets/PTP x 5 units)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Unimed Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.